Clinical trials: Steatosis
Type 2 Diabetes, Coronary Heart Disease
NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP)
PREMAP invites residents of the Eloisa region (South Savo, Finland) turning 45, 50, or 55 years of age in 2026 to undergo a blood-based NMR metabolomics risk assessment for five interlinked cardio-renal-metabolic conditions (type…
- Conditions
- Type 2 Diabetes, Coronary Heart Disease, Myocardial Infarction, Cerebrovascular Disease
- Trial name
- PREMAP (NCT07820800)
- Testing
- Digital health interventions
- Where
- Finland
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Eastern Finland
Cerebrovascular Disorders
Neuroprotective and Cardioprotective Effects Of Palm Vitamin E Tocotrienols
The purpose of the study is to assess the neuroprotective, anti atherogenic and hepatoprotective properties of tocotrienols (palm vitamin E) supplementation as determined by white matter lesion load on serial magnetic resonance…
- Trial name
- NCT00753532
- Where
- Malaysia
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Universiti Sains Malaysia
Metabolic Dysfunction-associated Steatohepatitis
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in…
- Trial name
- NCT07288138
- Testing
- ECC4703, ECC0509
- Where
- 68 sites in United States
- Volunteers
- 160 people
- Sponsor
- Eccogene
NASH (Non-alcoholic Steato-hepatitis)
Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved NASH (non-alcoholic steato-hepatitis).
- Trial name
- NCT01406704
- Testing
- Rosiglitazone, alpha-lipoic acid, Rosiglitazone/alpha-lipoic acid
- Volunteers
- 26 people
- Sponsor
- Seoul St. Mary's Hospital
Non-alcoholic Fatty Liver Disease (NAFLD)
How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?
The hypothesis of this study is that a diet high in sugars will increase abnormalities in blood lipids which are associated with increased cardiovascular disease risk, relative to a diet which is low in sugar.
- Trial name
- CHOT (NCT01790984)
- Testing
- High sugar low starch diet, Low sugar high starch diet
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bruce A. Griffin
Liver Fibrosis Progression in Chronic Liver Disease
LIVER FIBROSIS PREVALENCE IN FRANCE
"Mortality related to complications of cirrhosis, (hemorrhage, hepatic insufficiency and primary liver cancer) is 15,000 per year in France.
- Trial name
- FIBROFRANCE (NCT01927133)
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
PCOS, NAFLD
Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome
This study was planned to examine the prevalence of vitamin D insufficiency, insulin resistance, non-alcoholic fatty liver disease (NAFLD), and their relationship with each other and the nutritional status of individuals with…
- Trial name
- NCT05843955
- Testing
- Questionnaire
- Where
- Turkey (Türkiye)
- Volunteers
- 72 people
- Sponsor
- Hacettepe University
Fatty Liver
A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)
The purpose of this study is to determine whether cysteamine will effectively reduce or reverse the biologic markers of steatohepatitis in patients.
- Trial name
- NCT00799578
- Testing
- Cysteamine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Joel Lavine
MAFLD
Clinical Study on the Treatment of MAFLD With Ganzhixiao Capsules
This trial is expected to enroll 138 MAFLD patients in one clinical center, who will be randomly divided into a placebo group and a Ganzhixiao capsule group in a 1:1 ratio.
- Trial name
- NCT06848907
- Testing
- ganzhixiao capsule
- Volunteers
- 138 people
- Sponsor
- Dong Hui
Familial Partial Lipodystrophy, Hypertriglyceridemia
Study of Gemcabene in Adults With FPLD
The overall objective of this study is to assess the efficacy and safety of two dosing regimens of gemcabene (300 mg once daily for 24 weeks or 300 mg daily for 12 weeks followed by 600 mg daily for 12 weeks) in up to eight…
- Conditions
- Familial Partial Lipodystrophy, Hypertriglyceridemia, Fatty Liver, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NCT03508687
- Testing
- 300mg Gemcabene, 600mg Gemcabene
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Elif Oral
Metabolic Syndrome, Obesity
Observational Cohort of Pancreatic Echo-endoscopy
Metabolic syndrome is defined by the presence of at least two of the following five criteria: abdominal perimeter> 94 cm in men, 80 cm in women, high triglycerides, low HDL cholesterol, HTA and hyperglycemia.
- Conditions
- Metabolic Syndrome, Obesity, Hepatic Steatosis
- Trial name
- OBELIX (NCT04226014)
- Testing
- Endoscopic ultrasound
- Where
- 5 sites in France
- Volunteers
- 97 people
- Sponsor
- Centre Hospitalier Saint Joseph Saint Luc de Lyon
Type2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease
Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
This study focuses on the effects of Henagliflozein on hepatic fat content in patients with type 2 diabetes mellitus (DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- HHTN (NCT06449833)
- Testing
- Henagliflozein and Metformin, Linagliptin and Metformin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhujiang Hospital
Metabolic Dysfunction Associated Fatty Liver Disease
Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease
This study aims to investigate abnormalities in glycine-dependent metabolic pathways in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and evaluate whether dietary glycine supplementation improves…
- Trial name
- NCT07285135
- Testing
- Glycine
- Where
- Singapore
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Non-alcoholic Steatohepatitis
Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females
Objectives: Primary objective_To evaluate the safety and tolerability after single oral administration of the investigational product (IP), J2H-1702 in healthy female subjects.
- Trial name
- NCT06308874
- Testing
- Amg dose administration group, Bmg dose administration group
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- J2H Biotech
Nonalcoholic Fatty Liver Disease
Elucidating Growth Hormone Dynamics at Stages of Progressive Nonalcoholic Fatty Liver Disease
The purpose of this study is to investigate relationships between the body's growth hormone "axis" and nonalcoholic fatty liver disease.
- Trial name
- NCT06166797
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Non-Alcoholic Steatohepatitis
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to determine if the investigational treatment volixibat (SHP626) is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT02787304
- Testing
- SHP626
- Where
- 65 sites in United States, Canada and 2 more
- Volunteers
- 197 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Non-alcoholic Fatty Liver Disease, Obesity
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
STUDY OBJECTIVE: To explore the clinical efficacy and safety of liraglutide in obesity combined with metabolism-associated fatty liver disease (MAFLD).
- Trial name
- NCT06501326
- Testing
- Liraglutide, Orlistat
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Affiliated Hospital of Nantong University
Atherosclerosis, Cardiovascular Risk Factor
Early Vascular Ageing in the YOUth
This is a single-center observational study on adolescents to determine predictors of the early steps of the formation of atherosclerosis and to quantify their influence on Intima-Media-Thickness of the carotid artery and the…
- Conditions
- Atherosclerosis, Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Pathology
- Trial name
- EVA4YOU (NCT04598685)
- Where
- Austria
- Volunteers
- 1,517 people, healthy volunteers welcome
- Sponsor
- VASCage GmbH
Fatty Liver
Randomized Study of the Use of Intravenous Choline Supplementation in Long Term Total Parenteral Nutrition
OBJECTIVES: I. Determine whether intravenous choline supplementation will reverse the hepatic steatosis and improve liver function in patients who receive long term total parenteral nutrition.
- Trial name
- NCT00004697
- Testing
- choline chloride
- Volunteers
- 15 people
- Sponsor
- University of Texas
Non-alcoholic Fatty Liver Disease
Breath Analysis Using an Electronic Nose in Non Alcoholic Fatty Liver Disease
The purpose of this is to analyse human exhaled breath by means of a device called electronic nose(eNose) in patients with non-alcoholic fatty liver disease (NAFLD) as a way to non-invasive assessment of liver disease.This device…
- Trial name
- BEN (NCT02950610)
- Testing
- Breath analysis - electronic signature "Breath-print"
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.